ArticleArthritis research & therapy2026
Clinical and MRI remission in axial spondyloarthritis: one-year outcomes and predictors from the TRACE treat-to-target study with secukinumab.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03639740 (TReat-to-tArget), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
TReat-to-tArget (T2T) With seCukinumab in Axial Spondyloarthritis. IdEntification of MRI and Biochemical Biomarkers for Disease Activity, Treatment Response and Structural Damage Progression (the TRACE Study)
Who cites it
1 citing paper in PubMed.
- Correction: Clinical and MRI remission in axial spondyloarthritis: one-year outcomes and predictors from the TRACE treat-to-target study with secukinumab.Arthritis research & therapy · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEvidence on treat-to-target strategies in axial spondyloarthritis (axSpA) remains limited. We evaluated 1-year clinical and MRI outcomes of a secukinumab-based dose-escalation treat-to-target strategy aiming for clinical remission (ASDAS < 1.3), and investigated predictors of clinical and MRI-remission.
methodsTRACE (NCT03639740), was an investigator-initiated, prospective multicentre study including biologic-naïve patients with active axSpA. All patients initiated secukinumab 150mg; those not achieving clinical remission escalated to 300mg; patients still not reaching clinical remission switched to TNF-inhibitors. Sacroiliac joint (SIJ) and spine MRI were performed at baseline and weeks (w) 4, 16, 24, and 56 and centrally scored using SPARCC and CANDEN systems. Predictors of w16 and w56 remission were assessed using multivariable logistic regression.
resultsOf 90 included patients, 54 completed w56; 24, 8, and 22 received secukinumab 150mg, 300mg, and TNF-inhibitors, respectively. Overall, 32 patients (59%) achieved w56-clinical-remission. From week 0–56, total MRI-inflammation (SIJ + spine) decreased from mean 39.0 to 6.7, with 43% achieving w56-MRI-remission (SPARCC-SIJ ≤ 1 + CANDEN-spine ≤ 2). Structural lesion remodelling was evident by w4 and sustained through w56 (erosion decreased, fat lesion and backfill increased, new bone formation/ankylosis unchanged). Changes in MRI-inflammation and structural lesions were comparable irrespective of w56-clinical-remission status and treatment at w56. Independent baseline predictors were: Of w16-clinical-remission: ASDAS and BMI; Of w56-clinical-remission: none; Of w16-MRI-remission: female sex, lower MRI-inflammation and higher MRI-erosion score; Of w56-MRI-remission: lower MRI-inflammation and HLA-B27 positivity.
conclusionA 1-year secukinumab-based treat-to-target strategy in axSpA patients provided rapid and sustained clinical improvement, MRI-inflammation reduction and structural remodelling. BMI, sex, HLA-B27 and clinical/MRI disease activity predicted clinical and MRI-remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.